R&D channel feed – Endpoints News

R&D channel feed

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger

8 years ago

On a roll, Apellis adds positive PhII C3 data for AMD drug, preps for PhIII

8 years ago

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

8 years ago

AstraZeneca researchers plumb positive data to back extended use of Brilinta

8 years ago

Eli Lilly partners at CRUK tackle the first human study of a new p53-targeted cancer drug

8 years ago

PhIII bust forces Ultragenyx to scrap drug for rare muscle disease

8 years ago

Struggling AstraZeneca ups the ante on mRNA pipeline work

8 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2017

8 years ago

With CAR-T marketing looming, early study highlights potential of TCR engineering

8 years ago

Pfizer's CD22-targeted cancer drug inotuzumab wins an accelerated OK at FDA

8 years ago

Arcus grabs US rights to a WuXi-built PD-1 as second wave of checkpoints builds

8 years ago

Novo's semaglutide handily whips Eli Lilly's Trulicity in a PhIII diabetes showdown

8 years ago

Bristol-Myers shares sink after another setback for its immuno-oncology franchise drugs

8 years ago

Drug developers face increasingly risky tightrope walk between top-line results and hard data

8 years ago

With an eye on the FDA, Lexicon and Sanofi line up more positive data on diabetes drug

8 years ago

In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure

8 years ago

Zynerba shares crushed (again) as back-to-back flops leave lead drug under a cloud

8 years ago

Novartis partner Ophthotech says wet-AMD drug Fovista goes 0-for-3 in PhIII

8 years ago

Here's why Sucampo paid $200M for its PhIII Niemann-Pick drug

8 years ago

Gushing red ink, biotech billionaire Soon-Shiong slashes staff at NantHealth by 300, sells assets

8 years ago

Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?

8 years ago

Galapagos spotlights an 'exciting' round of PoC data for IPF drug, shares surge

8 years ago

Trying to turn a new leaf, Valeant ‘blockbuster’ can’t shed an R&D jinx

8 years ago

Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review

8 years ago

First page Previous page 292 293 294295296 297 298 Next page Last page